Immunogenicity of antitumor necrosis factor therapy in patients with spondyloarthritis
-
Ines Mahmoud
,
Aicha Ben Tekaya
Abstract
Objectives
To evaluate the serum dosage of the biomedicine (DBM) and the incidence of antidrug antibody (ADA) against antitumor necrosis factor (TNF) in spondyloarthritis, and to demonstrate the influence of these parameters on the clinical efficiency.
Methods
We conducted a cross-sectional multicentric study including patients with spondylarthritis (SpA) under antiTNF (infliximab [INF], etanercept [ETA] and adalimumab [ADL]) for at least 6 months. A dosage of the ADA and DBM were practiced by the immuno-enzymatic essay.
Result
Seventy one patients were recruited. Disease modifying antirheumatic drugs (DMARDs) were associated with anti-TNF in 30%. ADA was positive in 54% for INF, 33% for ADL and 0% for ETA with a significant difference(p<0.0001). Immunogenicity was correlated to a bad therapeutic response (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]≥4)(p=0.04). The DBM was inversely correlated with the rate of ADA for patients treated with INF(p<0.0001) and ADL(p<0.0001). The DBM was also inversely correlated with BASDAI of INF(p=0.03) and ADL (p=0.01). ADA was significantly associated with an anterior switch of anti TNF(p=0.04), the use of INF(p=0.002), presence of coxitis(p=0.01) and higher body mass index (BMI)(p=0.007). DMARDs associated with anti TNF were not a protective factor for positive ADA. In a multivariate study, only INF and BMI were independent factors of positive ADA.
Conclusion
The ADA formation lowered the DBM and favored the therapeutic failure.
Acknowledgments
We thank the departments of rheumatology for assistance, access to patients and for comments that greatly improved the manuscript. We would also like to show our gratitude to the department of immunology for facilitating the blood collection and fast results during this research
Research funding: None declared.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: Our study complies with the Declaration of Helsinki. Our locally appointed ethics committee has approved the research protocol and informed consent has been obtained from the subjects.
References
1. Moreland, LW, Baumgartner, SW, Schiff, MH, Tindall, EA, Fleischmann, RM, Weaver, AL, et al.. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141–7. https://doi.org/10.1056/nejm199707173370301.Search in Google Scholar
2. Bartelds, GM, Krieckaert, CL, Nurmohamed, MT, van Schouwenburg, PA, Lems, WF, Twisk, JW, et al.. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. J Am Med Assoc 2011;305:1460–8. https://doi.org/10.1001/jama.2011.406.Search in Google Scholar
3. van Schouwenburg, PA, Rispens, T,Wolbink, GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9:164–72. https://doi.org/10.1038/nrrheum.2013.4.Search in Google Scholar
4. Garcês, S, Demengeot, J, Benito-Garcia, E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947–55. https://doi.org/10.1136/annrheumdis-2012-202220.Search in Google Scholar
5. Radstake, TR, Svenson, M, Eijsbouts, AM, van den Hoogen, FH, Enevold, C, van Riel, PL, et al.. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739–45. https://doi.org/10.1136/ard.2008.092833.Search in Google Scholar
6. Vincent, FB, Morand, EF, Murphy, K, Mackay, F, Mariette, X, Marcelli, C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165–78. https://doi.org/10.1136/annrheumdis-2012-202545.Search in Google Scholar
7. Zhao, S, Mysler, E, Moots, RJ. Etanercept for the treatment of rheumatoid arthritis. Immunotherapy 2018;10:433–45. https://doi.org/10.2217/imt-2017-0155.Search in Google Scholar
8. Garcês, S, Demengeot, J, Benito-Garcia, E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947–55. https://doi.org/10.1136/annrheumdis-2012-202220.Search in Google Scholar
9. Braun, J, van den Berg, R, Baraliakos, X, Boehm, H, Burgos-Vargas, R, Collantes-Estevez, E, et al.. 2011Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis (AS). Ann Rheum Dis 2010;70:896–904.10.1136/ard.2011.151027Search in Google Scholar PubMed PubMed Central
10. Balsa, A, Lula, S, Marshall, L, Szczypa, P, Aikman, L. The comparative immunogenicity of biologic therapy and it sclinical relevance in psoriatic arthritis: a systematic review of the literature. Expert OpinBiolTher 2018;18:575–84. https://doi.org/10.1080/14712598.2018.1450385.Search in Google Scholar
11. Mease, PJ, Kivitz, AJ, Burch, FX, Siegel, EL, Cohen, SB, Ory, P, et al.. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264–72. https://doi.org/10.1002/art.20335.Search in Google Scholar
12. Antoni, C, Krueger, GG, de Vlam, K, Birbara, C, Beutler, A, Guzzo, C, et al.. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150–7. https://doi.org/10.1136/ard.2004.032268.Search in Google Scholar
13. Anderson, P, Louie, J, Lau, A, Broder, M. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 2005;7:3–9. https://doi.org/10.1007/s11926-005-0002-2.Search in Google Scholar
14. Emi Aikawa, N, de Carvalho, JF, Artur Almeida Silva, C, Bonfa, E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010;38:82–9. https://doi.org/10.1007/s12016-009-8140-3.Search in Google Scholar
15. Jung, SM, Kim, H-S, Kim, H-R, Kim, NY, Lee, J-H, Kim, J, et al.. Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis. IntImmunopharmacol 2014;21:20–5. https://doi.org/10.1016/j.intimp.2014.04.006.Search in Google Scholar
16. Kiely, PDW. Biologic efficacy optimization—a step towards personalized medicine. Rheumatology. 2016;55:780–8. https://doi.org/10.1093/rheumatology/kev356.Search in Google Scholar
17. Gremese, E, Carletto, A, Padovan, M, Atzeni, F, Raffeiner, B, Giardina, AR, et al.. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res 2013;65:94–100. https://doi.org/10.1002/acr.21768.Search in Google Scholar
18. Jani, M, Chinoy, H, Warren, RB, Fu, B, Griffiths, CE, Morgan, AW, et al.. Influence of immunogenicity and drug levels on the efficacy of long-term treatment of rheumatoid arthritis with adalimumab and etanercept: a UK-based prospective study. Ann Rheum Dis 2014;73:i89–90. https://doi.org/10.1136/annrheumdis-2014-eular.3811.Search in Google Scholar
19. Lorenz, HM, Behrens, F, Lippe, R, Jobst, J, Löschmann, PA, Meier, L. Etanercept as monotherapy or in combination with conventional DMARDs in psoriatic arthritis: results from a large prospective multicenter observational study. Ann Rheum Dis 2015;74 (Suppl 2):THU0415.10.1136/annrheumdis-2015-eular.2788Search in Google Scholar
20. Plasencia, C, Pascual-Salcedo, D, Nuño, L, Bonilla, G, Villalba, A, Peiteado, D, et al.. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012;71:1955–60. https://doi.org/10.1136/annrheumdis-2011-200828.Search in Google Scholar
21. Murdaca, G, Negrini, S, Magnani, O, Penza, E, Pellecchio, M, Puppo, F. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. Expet Opin Drug Saf 2017;16:1173–9. https://doi.org/10.1080/14740338.2017.1361404.Search in Google Scholar
22. Morales-Lara, MJ, Cañete, JD, Torres-Moreno, D, Hernández, MV, Pedrero, F, Celis, R, et al.. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Jt Bone Spine Rev Rhum 2012;79:591–6. https://doi.org/10.1016/j.jbspin.2012.02.003.Search in Google Scholar
23. de VriesMK, Wolbink, GJ, Stapel, SO, de Vrieze, H, van Denderen, JC, Dijkmans, BA, et al.. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66:1252–4. https://doi.org/10.1136/ard.2007.072397.Search in Google Scholar
24. Bornstein, G, Lidar, M, Langevitz, P, Fardman, A, Ben-Zvi, I, Grossman, C. The prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis. Clin Exp Rheumatol 2018;36:228–32.Search in Google Scholar
25. Arends, S, Lebbink, HR, Spoorenberg, A, Bungener, LB, Roozendaal, C, van der Veer, E, et al. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28:661–8.Search in Google Scholar
26. AIRE-MB Group, Senabre Gallego, JM, Rosas, J, Marco-Mingot, M, García-Gómez, JA, Santos-Soler, G, et al.. Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis. Rheumatol Int 2019;39:841–9. https://doi.org/10.1007/s00296-019-04288-7.Search in Google Scholar
27. Kneepkens, EL, Wei, JC-C, Nurmohamed, MT, Yeo, K-J, Chen, CY, van der Horst-Bruinsma, IE, et al.. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis 2015;74:396–401. https://doi.org/10.1136/annrheumdis-2013-204185.Search in Google Scholar
28. Cludts, I, Spinelli, FR, Morello, F, Hockley, J, Valesini, G, Wadhwa, M. Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine 2017;96:16–23. https://doi.org/10.1016/j.cyto.2017.02.015.Search in Google Scholar
29. de Vries, MK, Brouwer, E, van der Horst-Bruinsma, IE, Spoorenberg, A, van Denderen, JC, Jamnitski, A, et al.. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009;68:1787–8. https://doi.org/10.1136/ard.2009.109702.Search in Google Scholar
30. Koren, E, Smith, HW, Shores, E, Shankar, G, Finco-Kent, D, Rup, B, et al.. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008;333:1–9. https://doi.org/10.1016/j.jim.2008.01.001.Search in Google Scholar
31. Gorovits, B. Antidrug antibody assay validation: industry survey results. AAPS J 2009;11:133–8. https://doi.org/10.1208/s12248-009-9091-6.Search in Google Scholar
32. Hart, MH, de VriezeH,WoutersD,Wolbink, GJ, Killestein, J, de Groot, ER, et al.. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011;372:196–203. https://doi.org/10.1016/j.jim.2011.07.019.Search in Google Scholar
33. Aarden, L, Ruuls, SR, Wolbink, G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008;20:431–5. https://doi.org/10.1016/j.coi.2008.06.011.Search in Google Scholar
© 2020 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Review
- Herbal approach for the management of C0VID-19: an overview
- Original Articles
- Clinically important drug–drug interactions in patients admitted to hospital with COVID-19: drug pairs, risk factors, and management
- Spinal and general anesthesia produces differential effects on oxidative stress and inflammatory cytokines in orthopedic patients
- Immunogenicity of antitumor necrosis factor therapy in patients with spondyloarthritis
- Biochip-based approach for comprehensive pharmacogenetic testing
- Clinical efficacy of Majoon Falasfa and Roghan-e-Surkh in post-stroke-disability: an open labeled, pre-post analysis
- Ascorbic acid improves extrapyramidal syndromes and corpus striatal degeneration induced by dopamine-2 receptor inhibition in Wistar rats
- Rutin ameliorates scopolamine-induced learning and memory impairments through enhancement of antioxidant defense system and cholinergic signaling
- Adansonia digitata L. leaf extract attenuates lead-induced cortical histoarchitectural changes and oxidative stress in the prefrontal cortex of adult male Wistar rats
Articles in the same Issue
- Frontmatter
- Review
- Herbal approach for the management of C0VID-19: an overview
- Original Articles
- Clinically important drug–drug interactions in patients admitted to hospital with COVID-19: drug pairs, risk factors, and management
- Spinal and general anesthesia produces differential effects on oxidative stress and inflammatory cytokines in orthopedic patients
- Immunogenicity of antitumor necrosis factor therapy in patients with spondyloarthritis
- Biochip-based approach for comprehensive pharmacogenetic testing
- Clinical efficacy of Majoon Falasfa and Roghan-e-Surkh in post-stroke-disability: an open labeled, pre-post analysis
- Ascorbic acid improves extrapyramidal syndromes and corpus striatal degeneration induced by dopamine-2 receptor inhibition in Wistar rats
- Rutin ameliorates scopolamine-induced learning and memory impairments through enhancement of antioxidant defense system and cholinergic signaling
- Adansonia digitata L. leaf extract attenuates lead-induced cortical histoarchitectural changes and oxidative stress in the prefrontal cortex of adult male Wistar rats
